Butoconazole

Summary

Butoconazole (CHEMBL1295) is an approved small molecule (ATC G01AF15).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AF15
• Chemistry: 411.8 Da · C19H17Cl3N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1295
Name	Butoconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	47472
ChEBI	CHEBI:3240
ATC	G01AF15
Molecular formula	C19H17Cl3N2S
Molecular weight	411.8
InChIKey	SWLMUYACZKCSHZ-UHFFFAOYSA-N

SMILES: C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl

IUPAC name: 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole

ChEBI definition: A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. An antifungal agent, it is used as its nitrate salt in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.

Also known as: Butoconazol, Butoconazole, Gynofort, NSC-758658, butoconazole, BUTOCONAZOLE, Butaconazol

Parent form; salt/anhydrous children: CHEMBL1200398

Patent coverage: 3,116 distinct patent families (12,122 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Alpha-2B adrenergic receptor, Glucocorticoid receptor, Estrogen receptor, Progesterone receptor, Type-1 angiotensin II receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Androgen receptor, Nuclear receptor subfamily 1 group I member 2, Voltage-dependent L-type calcium channel subunit alpha-1C, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 15 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	6.07	AC50	860	nM	CHEMBL_ACT_25188619
OPRK1	5.75	AC50	1800	nM	CHEMBL_ACT_25130000
KCNH2	5.23	AC50	5900	nM	CHEMBL_ACT_25118767
PGR	5.04	AC50	9100	nM	CHEMBL_ACT_25222581
P15207	5.04	AC50	9200	nM	CHEMBL_ACT_25232586

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).